Geneticists and pharmacologists understand that drug response is a process that depends on various factors, including age, co-morbidities, diet, and genetics. These attributes will have significant influences on the nature or quality of medical care available to the targeted patients. The genomics of a given person will dictate the genes that support the metabolism and transportation of various active compounds. Such variations explain why adverse events might emerge after an individual is subjected to a certain drug or records failure in treatment. Without a proper understanding of these responses, those involved in the care delivery process might be unable to meet the demands and health needs of the targeted patients.
Such a development might make it impossible for many people to record the expected or positive health outcomes. With this kind of knowledge, it becomes possible for pharmacists, scientists, and practitioners to focus on such variability of pharmacological responses and support the tailoring of pharmacologic agents to support or ensure that more individuals receive personalized medical services. This is an evidence-based practice whereby different stakeholders collaborate to produce high-quality drugs and support systems that are informed by the genetic factors of the patient.
This process explains why it has become possible for pharmacologists to produce a wide range of drugs that can overcome such personal or genetic factors, thereby supporting the changing health demands of the greatest number of patients. Future researchers can combine emerging technologies and ideas in order to learn more about this variability and present superior models or approaches for improving the quality of care to patients with diverse genetic backgrounds.